.
Previously, we reported that the expression of gelsolin, an actin-regulatory protein, is frequently silenced in various cancers including stomach, colon, urinary bladder and lung, and that gelsolin functions as a tumor-suppressor [3] [4] [5] [6] [7] . These findings were also demonstrated in breast and prostate cancers 8, 9 . On the other hand, a subset of non-small cell lung cancers is characterized by high expression levels of gelsolin correlated with lymphatic invasion 10 , and there was a gradual increase in gelsolin with an increase in tumor grade and stage in uroepithelial carcinoma 11 . Gelsolin induced invasion of epithelial cells as well as colon adenocarcinoma cells 12 . It is therefore possible that a decrease in expression during a particular stage is followed by an increase during another stage. To understand roles of gelsolin in the whole process of tumorigenesis, mechanisms for both down-and up-regulations should be analyzed. In breast cancers, gelsolin genes were not mutated, however epigenetic changes in the chromatin structure were responsible for the deficiency 13 . Histone deacetylase (HDAC) inhibitors, such as trichostatin A (TSA) and apicidin, selectively induced the expression of gelsolin 14, 15 . Recent studies have suggested a new mechanism for cell-specific gene regulation linking nuclear architecture, chromatin 5 structure and functional organization of DNA sequences 16 .
In an effort to determine the molecular basis of gelsolin downregulation in urinary bladder cancer and to better understand the carcinogenic process, we investigated the gelsolin promoter through the use of methylation-specific sequencing, luciferase assays and chromatin immunoprecipitation (ChIP) assays. Furthermore, we employed in vivo footprinting using the ligation mediated polymerase chain reaction (LM-PCR) to examine the DNA elements in the cis-acting region of the gelsolin promoter in an attempt to speculate the chromatin structure in this region and to identify potential DNA-protein interactions in cancer cells. 17, 18 and is mortal and very difficult to cultivate under some conditions such as TSA treatment. Exponentially growing cells were used in all experiments. For TSA treatment, cell lines were grown and plated into culture dishes, switched to medium containing TSA (Wako, Tokyo, Japan) at 0, 10, 100 and 500 ng/ml for 24h, or 500 ng/ml for 8, 16 and 24h.
MATERIALS AND METHODS

Cell cultures and chemicals
Mutational analysis
The gelsolin promoter from both normal (SV-HUC-1) and cancer (DAB-1) cells was amplified using PCR with the following primer pairs:
5'-TGCCCAAAGTTACAGGACT-3' (-599 to -581; S1), 5'-CTCCCCTACCTGCTGCTG-3' (+93 to +76; AS1). The PCR cycle consisted of a denaturation step at 94°C for 1 min, annealing at 57°C for 1 min, followed by elongation at 72°C for 1 min. The PCR products were sequenced using the following 4 primers: S1, 5'-GGCCCCAGCCCAGCTCAGGA-3' (-287 to -268; S2), AS1, 
Transient transfection and luciferase assay
The cells were seeded and pBgl II gelsolin promoter luciferase reporter (Fujita H.
unpublished data) was transfected with FuGene6 reagent (Roche Diagnostics, Mannheim, Germany) in triplicate. After incubation for 48h, luciferin substrate (Promega Corp., Madison, WI) was added, and the luminescence was measured using the Picagene kit (Toyoinki, Tokyo, Japan) and a Berthold Lumat LB9501
luminometer. Cells were co-transfected with pSV beta bas an internal control and the luciferase activity was normalized. In an effort to determine whether the acetylation of histones alters promoter activity, transfected cells were incubated with various doses of TSA as described above. Relative luciferase activities were standardized relative to an untreated control.
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Western blot analysis
Purified gelsolin protein was produced with human cytoplasmic gelsolin expression plasmid pET-11a (Novagen, San Diego, CA) in E. coli as described previously 
In vivo dimethylsulfate (DMS) footprinting
The LM-PCR for in vivo DMS footprinting was performed as described previously 20, 21 . from LM-PCR products were determined from the guanine ladders of control naked DNA and our revised sequence information (Fig. 1) .
In vivo KMnO 4 treatment
Potassium permanganate (KMnO 4 ) modification of whole cells was performed as described previously 23 . Naked genomic DNA from human epidermoid carcinoma 11
RESULTS
Mutation and methylation
Some molecular mechanisms resulting in the silencing of the gelsolin gene in cancer cells can include gene mutation, DNA methylation and alteration of chromatin structure. We first carried out direct sequencing of the gelsolin promoter (from -580 to +75, relative to the transcription start site) using the PCR products derived from human bladder cancer cells (DAB-1, KU-7, and UMUC-2) and the cells derived from normal uroepithelium (SV-HUC-1). Although it was found that the gelsolin promoter of cancer and normal tissue-derived cells were identical in sequence, this sequence differed from that previously reported at two nucleotide positions: -153 G (from K which shows G or T in the original report 24 ) and -170 T (our addition) from the transcription start site (Fig. 1) .
The gelsolin gene promoter sequence is rich in G/C and contains many CpG sites.
Forty CpG sites were found in the region 600 bp upstream from the transcription start site with 25 of these being clustered between -229 to -5. Bisulfite sequencing analysis using cancer (UMUC-2, DAB-1) cells and the cells derived from normal uroepithelium (SV-HUC-1) showed no difference in the methylation state of these cells, and all CpG sites in the proximal promoter region were unmethylated (data not shown).
Effect of trichostatin A on promoter activity and protein expression
In an effort to determine the effects of TSA on the gelsolin promoter, bladder 
Histone deacetylation
Since TSA seems to have many effects on cells besides inhibiting histone deacetylase, we analyzed the fluctuation in histone acetylation levels at the gelsolin promoter using the ChIP assay. DNA fragments were purified from immunoprecipitated material using antibodies against acetylated histones H3 and H4, respectively. These fragments were dot blotted and hybridized with the probe 3.8-fold (KU-7) and 6.6-fold (UMUC-2). Similar trends were observed with acetylated histone H4: 8.3-fold (DAB-1), 1.9-fold (KU-7) and 3.3-fold (UMUC-2) (Fig. 3) . These results suggest that the increase in gelsolin promoter activity and consequent induction of gelsolin protein synthesis by TSA are mediated by a histone deacetylase inhibitor, and that the histones associated with the gelsolin promoter in bladder cancer cells are hypoacetylated.
In vivo DMS footprinting
In vivo DMS footprinting was performed in an effort to identify the presence of sequence-specific transcription factors bound to the gelsolin gene promoter, and to relate these findings to changes in the histone acetylation status. We have characterized the gelsolin promoter region from -235 to +1 using three primer sets (L1 -L3, L4 -L6 and U1 -U3). In the case of the distal region of the promoter, we conducted in vivo footprinting using the L1 -L3 primer set, as shown in Fig. 4A . We 
In vivo KMnO 4 analysis
In an effort to obtain evidence supporting the presence of a stem and loop structure at the gelsolin gene promoter, we carried out LM-PCR analysis using Western blot analysis of gelsolin proteins in DAB-1 and KU-7 cancer and immortalized uroepithelial SV-HUC-1 cells were compared and quantified using purified gelsolin standards. These cells were treated with various concentrations of TSA (0, 10, 100, 500 ng/ml) for 24h using anti-gelsolin and anti-actin antibodies.
Normal uroepithelial HMKU-1 cells, that fully express gelsolin, were also used as positive controls. 
